| Drug Name |
Pemetrexed disodium |
| Drug ID |
BADD_D01702 |
| Description |
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small cell lung cancer has also been investigated. |
| Indications and Usage |
Used in combination with cisplatin for the treatment of malignant pleural mesothelioma in adults whose disease is unresectable or who otherwise are not candidates for potentially curative surgery. Also used as a monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy |
| Marketing Status |
Prescription |
| ATC Code |
L01BA04 |
| DrugBank ID |
DB00642
|
| KEGG ID |
D03828
|
| MeSH ID |
D000068437
|
| PubChem ID |
135413520
|
| TTD Drug ID |
D0Y4GO
|
| NDC Product Code |
0002-2059; 62381-7623; 63759-0007; 0002-7623; 63660-0008; 62381-7640; 76302-017; 0002-2060; 29930-243; 49386-004; 0002-7640 |
| Synonyms |
Pemetrexed | MTA | N-(4-(2-(2-amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-d)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid | Pemetrexed Disodium | Disodium, Pemetrexed | LY 231514 | 231514, LY | LY-231,514 | LY231514 | LY 231,514 | 231,514, LY | LY-231514 | Alimta |
